Detalhe da pesquisa
1.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863358
2.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
3.
High-affinity memory B cells induced by conjugate vaccines against weak tumor antigens are vulnerable to nonconjugated antigen.
Blood
; 118(3): 650-9, 2011 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-21613251
4.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect
; 87(1): 18-26, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37085049
5.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Lancet Infect Dis
; 22(8): 1131-1141, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550261
6.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
J Infect
; 84(6): 795-813, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405168
7.
Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study.
Lancet Respir Med
; 8(12): 1192-1200, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33038974
8.
CD27 in defining memory B-cell origins in Waldenström's macroglobulinemia.
Clin Lymphoma Myeloma
; 9(1): 33-5, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19362967
9.
Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines.
Cancer Res
; 66(8): 3996-4000, 2006 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16618718
10.
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
J Infect
; 86(5): 540-541, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055303
11.
Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression.
Clin Lymphoma
; 5(4): 285-9, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15794867
12.
Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator.
Methods Mol Med
; 115: 129-44, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15998966
13.
Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events.
Blood
; 103(7): 2795-8, 2004 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14551145
14.
Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch.
Blood
; 104(10): 3312-7, 2004 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15284115
15.
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.
Blood
; 101(12): 4975-81, 2003 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12609845